查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
虚拟临床试验全球市场研究报告——2023-2030 年行业分析、规模、研究、增长、趋势和预测
市场调查报告书
商品编码
1267304

虚拟临床试验全球市场研究报告——2023-2030 年行业分析、规模、研究、增长、趋势和预测

Global Virtual Clinical Trials Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

全球对虚拟临床试验市场的需求将从 2022 年的 122.4 亿美元增长到 2030 年的近 261.2 亿美元，在 2023 年至 2030 年的研究期间预计将达到 9.94% 的复合年增长率。

虚拟临床试验是由技术推动的临床试验技术。 虚拟方法使您可以在家参加临床试验，并在来访困难时继续学习。 因此，我们可以提供创新工具来收集临床试验参与者的安全性和有效性信息。 这些解决方案在技术、高级软件、小工具、在线社交网站、机器人过程自动化、机器学习等方面具有无数优势。 这些虚拟临床试验方便、实惠且以患者为中心。

市场力量：

虚拟临床试验正变得越来越流行和发展，因为它们更舒适、以患者为中心且更具成本效益。 政府提高公众意识的努力也在推动虚拟临床试验市场的发展。 随着对用于临床目的的实用、省时、简单和安全平台的需求增加，这些试验的市场规模也有望增长。 随着许多製造商资助研发，市场也在扩大。 然而，公众认知度低可能会阻碍虚拟临床试验市场的扩张。

这份研究报告描述了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还对全球虚拟临床试验市场的每个细分市场进行全面评估。 虚拟临床试验行业的发展和趋势为这项研究提供了一种整体方法。

市场细分：

本部分提供有关国家和地区细分的详细数据，以帮助战略制定者确定各自产品和服务的目标受众，并帮助他们把握未来的商机。

通过研究设计

  • 干预
  • 观察类型
  • 扩大访问范围

通过显示

  • 中枢神经系统
  • 自身免疫/炎症
  • 心血管疾病
  • 代谢/内分泌学
  • 感染
  • 肿瘤学
  • 泌尿系统
  • 眼科
  • 其他

按阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

按地区分析：

本部分介绍了区域前景，重点关注北美、欧洲、亚太地区、拉丁美洲、中东和非洲虚拟临床试验市场当前和未来的需求。 此外，我们还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 虚拟临床试验市场的主要参与者有 ICON PLC、Parexel International Corporation、IQVIA、Covance、PRA Health Sciences、LEO Innovation Lab、Medidata、Oracle、CRF Health、Clinical Ink、Medable Inc、Clinical Ink、Halo Health Systems、Croprime 等。是。 本节包括对竞争格局的全面了解，包括各种战略发展，例如主要併购、未来能力、合作伙伴关係、财务概览、合作、新产品开发和新产品发布。

内容

第一章前言

  • 报告内容
    • 目的
    • 目标受众
    • USP（独特的销售建议）及其提供的内容
  • 调查范围
  • 调查方法
    • 市场调研流程
    • 市场研究方法

第 2 章执行摘要

  • 市场亮点
  • 全球市场概况

第 3 章虚拟临床试验 - 行业分析

  • 简介 - 市场动态
  • 市场驱动力
  • 市场製约因素
  • 机会
  • 行业趋势
  • 波特的五力分析
  • 市场吸引力分析
    • 通过研究设计进行市场吸引力分析
    • 按适应症分类的市场吸引力分析
    • 按阶段分析市场吸引力
    • 市场吸引力分析：按地区

第四章价值链分析

  • 价值链分析
  • 原材料分析
    • 原材料清单
    • 原材料製造商列表
    • 主要原材料价格走势
  • 潜在买家名单
  • 营销渠道
    • 直接营销
    • 间接营销
    • 市场发展趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章虚拟临床试验的全球市场分析：按研究设计

  • 按研究设计总结
  • 过去和未来的数据
  • 研究设计分析
  • 干预
  • 观察类型
  • 扩大访问范围

第 7 章虚拟临床试验的全球市场分析：按适应症

  • 功效概述
  • 过去和未来的数据
  • 适应症分析
  • 中枢神经系统
  • 自身免疫/炎症
  • 心血管疾病
  • 代谢/内分泌学
  • 感染
  • 肿瘤学
  • 泌尿系统
  • 眼科
  • 其他

第 8 章虚拟临床试验的全球市场销售分析：按阶段

  • 阶段大纲
  • 过去和未来的数据
  • 阶段分析
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第 9 章虚拟临床试验的全球市场销售分析：按地区

  • 按地区进行的销售前景分析
  • 介绍销售分析
  • 北美销售分析
    • 概览、历史和预测销售分析
    • 北美各部门的销售分析
    • 北美销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史和预测销售分析
    • 按细分市场进行的欧洲销售分析
    • 按国家/地区划分的欧洲销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 意大利销售分析
    • 俄罗斯销售分析
    • 其他欧洲销售分析
  • 亚太地区销售分析
    • 概览、历史和预测销售分析
    • 亚太地区各部门的销售分析
    • 亚太国家/地区销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本的销售分析
    • 韩国销售分析
    • 澳大利亚销售分析
    • 其他亚太地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史和预测销售分析
    • 拉丁美洲各部门的销售分析
    • 拉丁美洲国家/地区的销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利的销售分析
    • 其他拉丁美洲销售分析
  • 中东和非洲销售分析
    • 概览、历史和预测销售分析
    • 中东和非洲各细分市场的销售额分析
    • 中东和非洲国家/地区的销售分析
    • 沙特阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 其他中东和非洲销售分析

第10章虚拟临床试验公司的竞争格局

  • 虚拟临床试验市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他扩展

第11章公司简介

  • 前 10 名公司的市场份额分析
  • 市场集中度
  • 图标PLC
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • Parexel 国际公司
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 艾昆纬
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 科文斯
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • PRA 健康科学
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • LEO 创新实验室
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • Medidata
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 甲骨文
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • CRF 健康
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 临床墨水
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 医疗公司
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 临床墨水
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • Halo 健康系统
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势
  • 克罗普莱姆
    • 公司概况
    • 企业收入
    • 产品介绍
    • 近期趋势

注意：公司简介中的财务信息和近期发展基于可用信息，可能不涵盖私营公司。

Product Code: VMR11219982

The global demand for Virtual Clinical Trials Market is presumed to reach the market size of nearly USD 26.12 BN by 2030 from USD 12.24 BN in 2022 with a CAGR of 9.94% under the study period 2023 - 2030.

A virtual clinical trial refers to clinical trial techniques facilitated by technology. A virtual approach enables individuals to participate in the trial from the convenience of their homes, ensuring that research may continue even when site visits are inconvenient. As a result, it provides an innovative tool for gathering safety and efficacy information from clinical study participants. These solutions consider the countless advantages of technology, advanced software, gadgets, online social networking sites, robotic process automation, machine learning, and others. These virtual clinical trials are convenient, affordable, and patient-focused.

Market Dynamics:

The virtual clinical trial approach is more comfortable, patient-centered, and cost-effective, so virtual trials are becoming more popular and are growing. The government's attempt to increase public awareness also assists in the market expansion of virtual clinical trials. As the demand for a practical, time-saving, easy, safe platform for clinical purposes grows, so does the market for these trials is expected to scale up. Moreover, the market is growing since a lot of manufacturers are funding R&D initiatives. However,lack of public awareness may hamper the expansion of the virtual clinical trial market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of virtual clinical trials. The growth and trends of virtual clinical trials industry provide a holistic approach to this study.

Market Segmentation:

This section of the virtual clinical trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Study Design

  • Interventional
  • Observational
  • Expanded Access

By Indication

  • CNS
  • Autoimmune/Inflammation
  • Cardiovascular Disease
  • Metabolic/Endocrinology
  • Infectious Disease
  • Oncology
  • Genitourinary
  • Ophthalmology
  • Others

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase Iv

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Virtual Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the virtual clinical trials market include ICON PLC, Parexel International Corporation, IQVIA, Covance, PRA Health Sciences, LEO Innovation Lab, Medidata, Oracle, CRF Health, Clinical Ink, Medable Inc, Clinical Ink, Halo Health Systems, Croprime. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . VIRTUAL CLINICAL TRIALS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Study Design
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Phase
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN

  • 6.1 Overview by Study Design
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Study Design
  • 6.4 Interventional Historic and Forecast Sales by Regions
  • 6.5 Observational Historic and Forecast Sales by Regions
  • 6.6 Expanded Access Historic and Forecast Sales by Regions

7 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

  • 7.1 Overview by Indication
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Indication
  • 7.4 CNS Historic and Forecast Sales by Regions
  • 7.5 Autoimmune/Inflammation Historic and Forecast Sales by Regions
  • 7.6 Cardiovascular Disease Historic and Forecast Sales by Regions
  • 7.7 Metabolic/Endocrinology Historic and Forecast Sales by Regions
  • 7.8 Infectious Disease Historic and Forecast Sales by Regions
  • 7.9 Oncology Historic and Forecast Sales by Regions
  • 7.10. Genitourinary Historic and Forecast Sales by Regions
  • 7.11 Ophthalmology Historic and Forecast Sales by Regions
  • 7.12 Others Historic and Forecast Sales by Regions

8 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET SALES ANALYSIS BY PHASE

  • 8.1 Overview by Phase
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Phase
  • 8.4 Phase I Historic and Forecast Sales by Regions
  • 8.5 Phase II Historic and Forecast Sales by Regions
  • 8.6 Phase III Historic and Forecast Sales by Regions
  • 8.7 Phase IV Historic and Forecast Sales by Regions

9 . GLOBAL VIRTUAL CLINICAL TRIALS MARKET SALES ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook Sales Analysis
  • 9.2. Introduction Sales Analysis
  • 9.3. North America Sales Analysis
    • 9.3.1. Overview, Historic and Forecast Sales Analysis
    • 9.3.2. North America By Segment Sales Analysis
    • 9.3.3. North America By Country Sales Analysis
    • 9.3.4. United State Sales Analysis
    • 9.3.5. Canada Sales Analysis
    • 9.3.6. Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1. Overview, Historic and Forecast Sales Analysis
    • 9.4.2. Europe by Segment Sales Analysis
    • 9.4.3. Europe by Country Sales Analysis
    • 9.4.4. United Kingdom Sales Analysis
    • 9.4.5. France Sales Analysis
    • 9.4.6. Germany Sales Analysis
    • 9.4.7. Italy Sales Analysis
    • 9.4.8. Russia Sales Analysis
    • 9.4.9. Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1. Overview, Historic and Forecast Sales Analysis
    • 9.5.2. Asia Pacific by Segment Sales Analysis
    • 9.5.3. Asia Pacific by Country Sales Analysis
    • 9.5.4. China Sales Analysis
    • 9.5.5. India Sales Analysis
    • 9.5.6. Japan Sales Analysis
    • 9.5.7. South Korea Sales Analysis
    • 9.5.8. Australia Sales Analysis
    • 9.5.9. Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1. Overview, Historic and Forecast Sales Analysis
    • 9.6.2. Latin America by Segment Sales Analysis
    • 9.6.3. Latin America by Country Sales Analysis
    • 9.6.4. Brazil Sales Analysis
    • 9.6.5. Argentina Sales Analysis
    • 9.6.6. Peru Sales Analysis
    • 9.6.7. Chile Sales Analysis
    • 9.6.8. Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1. Overview, Historic and Forecast Sales Analysis
    • 9.7.2. Middle East & Africa by Segment Sales Analysis
    • 9.7.3. Middle East & Africa by Country Sales Analysis
    • 9.7.4. Saudi Arabia Sales Analysis
    • 9.7.5. UAE Sales Analysis
    • 9.7.6. Israel Sales Analysis
    • 9.7.7. South Africa Sales Analysis
    • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE VIRTUAL CLINICAL TRIALS COMPANIES

  • 10.1. Virtual Clinical Trials Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11 . COMPANY PROFILES OF VIRTUAL CLINICAL TRIALS INDUSTRY

  • 11.1. Top 10 Company Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. ICON PLC
    • 11.3.1. Company Overview
    • 11.3.2. Company Revenue
    • 11.3.3. Products
    • 11.3.4. Recent Developments
  • 11.4. Parexel International Corporation
    • 11.4.1. Company Overview
    • 11.4.2. Company Revenue
    • 11.4.3. Products
    • 11.4.4. Recent Developments
  • 11.5. IQVIA
    • 11.5.1. Company Overview
    • 11.5.2. Company Revenue
    • 11.5.3. Products
    • 11.5.4. Recent Developments
  • 11.6. Covance
    • 11.6.1. Company Overview
    • 11.6.2. Company Revenue
    • 11.6.3. Products
    • 11.6.4. Recent Developments
  • 11.7. PRA Health Sciences
    • 11.7.1. Company Overview
    • 11.7.2. Company Revenue
    • 11.7.3. Products
    • 11.7.4. Recent Developments
  • 11.8. LEO Innovation Lab
    • 11.8.1. Company Overview
    • 11.8.2. Company Revenue
    • 11.8.3. Products
    • 11.8.4. Recent Developments
  • 11.9. Medidata
    • 11.9.1. Company Overview
    • 11.9.2. Company Revenue
    • 11.9.3. Products
    • 11.9.4. Recent Developments
  • 11.10. Oracle
    • 11.10.1. Company Overview
    • 11.10.2. Company Revenue
    • 11.10.3. Products
    • 11.10.4. Recent Developments
  • 11.11. CRF Health
    • 11.11.1. Company Overview
    • 11.11.2. Company Revenue
    • 11.11.3. Products
    • 11.11.4. Recent Developments
  • 11.12. Clinical Ink
    • 11.12.1. Company Overview
    • 11.12.2. Company Revenue
    • 11.12.3. Products
    • 11.12.4. Recent Developments
  • 11.13. Medable Inc
    • 11.13.1. Company Overview
    • 11.13.2. Company Revenue
    • 11.13.3. Products
    • 11.13.4. Recent Developments
  • 11.14. Clinical Ink
    • 11.14.1. Company Overview
    • 11.14.2. Company Revenue
    • 11.14.3. Products
    • 11.14.4. Recent Developments
  • 11.15. Halo Health Systems
    • 11.15.1. Company Overview
    • 11.15.2. Company Revenue
    • 11.15.3. Products
    • 11.15.4. Recent Developments
  • 11.16. Croprime
    • 11.16.1. Company Overview
    • 11.16.2. Company Revenue
    • 11.16.3. Products
    • 11.16.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers : Impact Analysis
  • Restraints : Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • List of Potential Buyers
  • Analysis by Study Design (USD MN)
  • Interventional Market Sales by Geography (USD MN)
  • Observational Market Sales by Geography (USD MN)
  • Expanded Access Market Sales by Geography (USD MN)
  • Analysis Market by Indication (USD MN)
  • CNS Market Sales by Geography (USD MN)
  • Autoimmune/Inflammation Market Sales by Geography (USD MN)
  • Cardiovascular Disease Market Sales by Geography (USD MN)
  • Metabolic/Endocrinology Market Sales by Geography (USD MN)
  • Infectious Disease Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Genitourinary Market Sales by Geography (USD MN)
  • Ophthalmology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Analysis by Phase (USD MN)
  • Phase I Market Sales by Geography (USD MN)
  • Phase II Market Sales by Geography (USD MN)
  • Phase III Market Sales by Geography (USD MN)
  • Phase IV Market Sales by Geography (USD MN)
  • Global Virtual Clinical Trials Market Sales by Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United State Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate by Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Virtual Clinical Trials Report
  • Market Research Process
  • Market Research Methodology
  • Global Virtual Clinical Trials Market Size, by Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis by Study Design
  • Market Attractiveness Analysis by Indication
  • Market Attractiveness Analysis by Phase
  • Market Attractiveness Analysis by Region
  • Value Chain Analysis
  • Global Market Analysis by Study Design (USD MN)
  • Interventional Market Sales by Geography (USD MN)
  • Observational Market Sales by Geography (USD MN)
  • Expanded Access Market Sales by Geography (USD MN)
  • Global Market Analysis by Indication (USD MN)
  • CNS Market Sales by Geography (USD MN)
  • Autoimmune/Inflammation Market Sales by Geography (USD MN)
  • Cardiovascular Disease Market Sales by Geography (USD MN)
  • Metabolic/Endocrinology Market Sales by Geography (USD MN)
  • Infectious Disease Market Sales by Geography (USD MN)
  • Oncology Market Sales by Geography (USD MN)
  • Genitourinary Market Sales by Geography (USD MN)
  • Ophthalmology Market Sales by Geography (USD MN)
  • Others Market Sales by Geography (USD MN)
  • Global Market Analysis by Phase (USD MN)
  • Phase I Market Sales by Geography (USD MN)
  • Phase II Market Sales by Geography (USD MN)
  • Phase III Market Sales by Geography (USD MN)
  • Phase IV Market Sales by Geography (USD MN)
  • Global Market by Revenue
  • North America Market by Revenue
  • Europe Market by Revenue
  • Asia Pacific Market by Revenue
  • Latin America Market by Revenue
  • Middle East & Africa Market by Revenue
  • Recent Development in Industry
  • Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.